Dermatology
Pityriasis Versicolor
4
Pipeline Programs↗
4
Active Trials↗
3
Companies Involved↗
Pityriasis Versicolor is an early-stage landscape with 4 programs across 3 companies. The most active players are Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Sebela Pharmaceuticals Development LLC, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 3
No programs
Analysis
Trial Status
7
clinical trials
Completed3 · 43%
Not yet recruiting3 · 43%
Recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor
Not yet recruiting·—·Phase 1/2·NCT07331792·86 enrolled
Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor
Completed·—·Phase 1·NCT05862714·164 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)